Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schering Albuterol Recall Linked With 24 Fatalities, Public Citizen Asserts

Executive Summary

Schering-Plough's testing of albuterol inhalers returned to the company shows that in every case where an injury is alleged to have occurred because of a faulty inhaler, the canister contained active ingredient, the company maintains.

You may also be interested in...



Schering GMP Criminal Investigation Continues After Consent Decree

Schering-Plough faces a potential criminal case regarding GMP violations after finalizing a consent agreement with FDA May 17

Schering-Plough Claritin DTC Ads Are Target Of Rx Consumer Litigation Group

A consumer litigation coalition lawsuit against Schering-Plough over direct-to-consumer advertising for Claritin (loratadine) is claiming that the company's DTC ads are misleading because they imply a higher degree of efficacy for the allergy drug than has been proven.

Schering-Plough Claritin DTC Ads Are Target Of Rx Consumer Litigation Group

A consumer litigation coalition lawsuit against Schering-Plough over direct-to-consumer advertising for Claritin (loratadine) is claiming that the company's DTC ads are misleading because they imply a higher degree of efficacy for the allergy drug than has been proven.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS038351

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel